Introduction
Gene therapy has demonstrated its clinical potential in hematopoietic disorders with significant success in the treatment of patients with severe combined immunodeficiency 1,2 and adenosine-deaminase deficiency. 3 These successful therapies were based on the reinfusion of gene-modified hematopoietic stem cells (HSCs). However, it has been demonstrated by several groups that purified HSCs may differentiate into or fuse with several non-hematopoietic cell (HC) types. [4] [5] [6] [7] [8] [9] [10] The ectopic expression of hematopoietic genes in non-hematopoietic tissues raises safety concerns. Further improvements in vector design to achieve specific and efficient expression of transgenes in target tissues would increase the safety of the procedure and are therefore desirable. This may also facilitate the application of gene therapy to other hematopoietic diseases.
Lentiviral vectors are among the most versatile of all integrating vector systems. 11 They are stable, easy to concentrate and have a broad tropism. Virtually all cell types analyzed, including those nondividing, can be efficiently transduced. The latest generation of lentiviral vectors are self-inactivating (SIN) and drive the expression of the transgene only through an internal promoter. 11 This has facilitated the development of transcriptionally regulated vectors. [12] [13] [14] The Wiskott-Aldrich syndrome (WAS) is a X-linked condition characterized clinically by profound and progressive immunodeficiency, eczema and severely decreased number of platelets (reviewed in Snapper and Rosen 15 and Thrasher 16 ). Patients with classical WAS have heterogeneous mutations in the WASP gene, [17] [18] [19] which usually result in the absence or very diminished expression of its encoded gene product (WASp), or otherwise give rise to non-functional truncated proteins. 20, 21 Expression of the WASP gene is restricted to cells of the hematopoietic lineage. 17, 22, 23 Petrella and co-workers 24 have characterized a 170 bp fragment containing four potential binding sites for hematopoietic transcription factors (two for Ets-1, one for c-Rel and one for PU.1) sufficient to confer hematopoietic-specific expression in transient assays. 24 Therefore, the WASP gene promoter is a good candidate to achieve hematopoietic-specific expression in the context of a SIN lentiviral vector.
Experimental models to study primary defects and to evaluate therapeutic alternatives when patient cells are not readily available include allospecific T-cell lines 25 as well as herpesvirus saimiri (HVS)-immortalized T-cell lines. 26 Very recently, we have demonstrated that HVSimmortalized T cells from WAS patients can efficiently be transduced by lentiviral vectors and are therefore a useful model for WAS gene therapy. 27 In this study, we show that a 500 bp fragment from the proximal WASP gene promoter, in the context of a SIN lentiviral vector, achieves hematopoietic-specific and physiologically relevant levels of WASp.
Results

Efficient transduction of hematopoietic and non-HCs by WW lentiviral vectors
The WASp-expressing lentiviral vectors used in this study are shown in Figure 1a . WPRE and enhanced green fluorescent protein (eGFP) sequences from the HRSIN-CSEW plasmid (SE) 28 were excised to obtain the SIN lentiviral backbone used to construct SW and WW vectors. cDNA sequences encoding WASP were cloned after the spleen focus-forming virus (SFFV) promoter to generate SW as described in Materials and methods. To construct WW, a 500 bp fragment from the proximal WASP gene promoter (extending from bases À1 to À499 from the transcriptional start site) was amplified by PCR and inserted in place of the SFFV promoter contained in the SW vector.
SW and WW lentiviral vectors expressed WASp protein in HVS-WAS/1 cells (derived from a WAS patient completely deficient in WASp) (Figure 1b , top panel) at the expected molecular weight (Figure 1c) . Both vectors exhibited similar transduction efficiencies on hematopoietic HVS-T cells (Figure 1b) , with titers over 10 6 TU/ml ( Table 1) . As expected, these titers were lower than those obtained with the WPRE-containing vector SE (Table 1) . Nevertheless, the intensity of WASp expression was slightly higher in SW-than in WW-transduced cells as suggested by the mean fluorescence intensity (MFI) within the R2-positive gate (Figure 1b) . In marked contrast, we did not detect any WASp expression in the non-hematopoietic RKO cells transduced with WW vectors (Table 1) , even though they were efficiently transduced (data not shown and Figure 3 ). As expected, SW and SE vectors containing the SFFV promoter transduced RKO cells with high efficiency (titers over 10 7 TU/ml) ( Table 1) .
Targeted WASp expression to HCs by WW lentiviral vectors
In order to determine whether the proximal WASP gene promoter confers hematopoietic-specific expression of WASp, two HC lines from different WAS patients (HVS-WAS/1 and ALLO-WAS/2) and three non-HCs (RKO, follicular dendritic cell (FDC) and HUVEC) were transduced with SW and WW lentiviral vectors at identical multiplicity of infection (MOI). HCs were transduced with an MOI ¼ 1 (as determined on HVS-WAS/1 cells) and the more permissive non-HCs with an MOI ¼ 0.2 in order to achieve similar transduction efficiencies. WASp expression levels were determined by flow cytometry based on the difference of MFI between cells in the positive R2 gate and negative R1 gate ( Figure 2a 
WASp expression confers a selective growth advantage to WW-transduced WASp-deficient T cells
We explored the possibility that expression of WASp could confer a selective advantage to transduced cells as it has been previously described in other systems. [29] [30] [31] [32] [33] Therefore, HVS-WAS/1 cells were transduced with the WW lentiviral vector at MOIs of 0.01, 0.1 and 1 and kept in culture for 39 days. The percentage of WASpexpressing cells was analyzed by flow cytometry at days 7, 27 and 39 after transduction. Figure 5a shows a robust increase in the percentage of WASp + cells over time in culture, indicating a selective growth advantage of transduced cells even in experiments where the starting WASp + population was lower than 1% (MOI of 0.1, solid circles). The cells were cultured in parallel with HVS-WAS/1 cells that had been transduced with the WE vector. Expression of eGFP driven by the WASP promoter did not affect cell growth characteristics (data not shown).
In order to corroborate these results, we performed a similar experiment with primary allospecific T cells from a second WAS patient (ALLO-WAS/2). ALLO-WAS/2 cells were transduced 5 days after stimulation and analyzed at days 7 and 34 after transduction. Vector copy number and WASp levels were analyzed by quantitative PCR and quantitative Western blotting as before. Figure 5b shows that WASp levels increased about 15 times from day 7 to day 34 (WASp/ERK ratio was 0.09 at day 7 and 1.43 at day 34). Vector copy number per cell was also increased about six times (Figure 6b , bottom), suggesting that expansion of cell populations with higher numbers of vector integrations had occurred. 
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A critical issue in HSC gene therapy approaches is to achieve adequate expression of the therapeutic gene in differentiated target cells. We therefore studied if the WASP promoter fragment used in the WW vector was able to drive transgene expression in human myeloid lineages derived from transduced hematopoietic progenitors. To determine this, we constructed a lentiviral vector (WE), which contains the backbone and promoter elements of WW vector but drives the expression of eGFP instead of WASp (see Materials and methods). CD34 + hematopoietic progenitors transduced with WE vectors were differentiated in methylcellulose medium and the colonies analyzed under fluorescence microscopy. Expression of eGFP was readily detectable in colonies from myeloid and erythroid lineages ( Figure  7a ). These data demonstrate that the WASP endogenous promoter in a context of a SIN lentiviral vector is able to achieve expression of the transgene in different hematopoietic lineages after transduction of human progenitors. Transduction efficiency of WE vector ranged from 30-70 percent among colonies from different hematopoietic lineages after one single round of transduction at MOI ¼ 2 (MOI estimated based on HVS-WAS/1 cells) (Figure 7b ).
Discussion
Gene therapy protocols for haematological and immunological disorders are often based in the re-infusion of gene-modified HSCs obtained using cell purification strategies. However, even purified HSCs populations may differentiate into or fuse with several non-HC types, such as hepatocytes, endothelial, epithelial, neuron or muscle cells. [5] [6] [7] [8] The expression of hematopoietic-specific . It would therefore be advantageous to develop vectors able to drive hematopoietic-specific expression of the therapeutic transgene.
Expression of WASp is normally restricted to HCs, including stem cells and progenitors. [22] [23] [24] WASp has well characterized roles in the functionality of immune cells and in the formation and survival of platelets. The biological activity of WASp in stem cell populations is witnessed by the apparent non-random distribution of X-inactivation in female carriers of a mutant WASP gene, 35 and the demonstration of homing and engraftment defects in mutant mice. 36 The widespread but hematopoietic-restricted expression profile of WASp is dictated by WASP gene regulatory elements which are therefore attractive for expression of many hematopoietic genes.
For this reason, we designed and tested lentiviral vectors incorporating proximal promoter sequences from the natural WASP gene. Previous functional characterization of the WASP gene promoter has been limited. 24, 37, 38 However, a 170 bp fragment 5 0 upstream of the transcription starting site does contain four potential binding sites for hematopoietic transcription factors (two for Ets-1, one for c-Rel, and one for PU.1) and is sufficient to confer preferential hematopoietic expression in transient reporter gene assays. 24 An alternate WASP promoter has been found 6 Kb upstream of the proximal promoter containing c-Myb and PU.1 binding sites 37 and has been suggested to have a role in WASp expression during the earlier stages of hematopoiesis. This also has not been functionally evaluated in detail.
We have shown that WASp expression regulated by proximal sequences of the WASP gene promoter in the context of an integrating vector system is transcriptionally targeted to HCs. A detailed analysis of cells transduced by vectors incorporating the SFFV LTR or the WASP gene proximal promoter showed that the latter is 135-350 times more efficient driving the expression of WASp in hematopoietic than in non-HCs. Interestingly, the activity (in terms of protein expression) of the WASP gene promoter in T cells was equivalent to that of the SFFV LTR, a highly potent regulatory element containing the duplicated enhancer sequences characteristic of many gammaretroviral vector LTRs. 39 Likewise, we have shown that a single WW vector integration is able to express protein levels that are close (0.34-0.63 times) to those found in normal cells. Therefore, the proximal WASP gene promoter in the context of a SIN lentiviral vector can also achieve physiologically relevant levels of WASp in transduced cells. In addition, we have demonstrated efficient transduction of both mouse and human hematopoietic progenitors, with preservation of gene expression following myeloid and erythroid differentiation. The proximal WASP gene promoter in the context of a SIN lentiviral vector may have useful characteristics for clinical trials of gene therapy for WAS as it achieves hematopoietic-specific and physiologically relevant levels of WASp. Expression of the WASP transgene confers a selective growth advantage to transduced T cells as described in spontaneous reversions of WAS patients [29] [30] [31] as well as in other models of CD3-activated WASp + cells. 32, 33 This observation indicates that the protein expressed in WW-transduced cells is functional. Furthermore, we have found that transduction of WAS-deficient T cells with the WW vector results in full reconstitution of cellular defects, including restoration of morphology and CD3-mediated responses (our unpublished data). We therefore propose that the WASP gene regulatory elements may provide a safer alternative to retroviral LTR sequences for the regulation of hematopoietic genes.
In summary, we have described the development of a SIN lentiviral vector that directs hematopoietic-specific, physiological transgene expression of a therapeutic gene (WASp) through the proximal WASP gene promoter. We believe that our data represent a significant step towards the goal of achieving controlled hematopoietic-specific transgene expression, an objective that is becoming of increasing interest in the light of vector-mediated cell transformation in animal models 34 and human clinical trials. 40 
Materials and methods
Cell lines and culture media
The generation and characterization of HVS-WAS/1 (derived from two WAS patients) as well as HVS-N (derived from a normal individual) have been described in detail. 26 Primary allospecific T cells from a second WAS patient (ALLO-WAS/2) (cared for by Dr N Matamoros, Hospital Son Dureta, Palma de Mallorca, Spain) and from a normal healthy individual (ALLO-NORMAL) were generated in our laboratory by mitomycin-C-treated Raji B-cell allospecific weekly stimulation as previously described in detail. 25 All HVS-T and allospecific cell lines were cultured in a mixture (1:1) of RPMI 1640 (Bio-Whittaker, Verviers, Belgium) and Panserin 401 (PAN Biotech, Aidenbach, Germany) media supplemented with 10% of fetal calf serum (FCS) (Gibco-BRL, Middlesex, UK), glutamine, penicillin-streptomycin and 50 UI/ml of recombinant human IL-2 (HoffmanLaRoche, Nutley, NJ, USA; kindly supplied by the National Institutes of Health AIDS reagent program, Rockville, MD, USA); RKO (colon adenocarcinoma cells) were grown in Dulbecco's modified Eagle's medium (Gibco), supplemented with 10% FCS, glutamine and antibiotics as above; and HUVEC (primary umbilical cord cells) were grown in endothelial cell growth medium (PromoCell, Heidelberg, Germany). Primary FDCs were obtained from human tonsils and cultured in RPMI 1640, containing 20% FCS until the cell line was established (usually 2 weeks). Jurkat T cells were cultured in RPMI 1640 supplemented as above, without the addition of rIL-2.
Plasmids
The HIV packaging (pCMVDR8.91) and vesicular stomatitis virus(VSV)-G (pMD.G) plasmids were kindly provided by D Trono. The packaging plasmid pCMVDR8.91 encodes gag, pol, tat and rev genes. The pMD.G plasmid encodes the VSV-G protein. The lentiviral vector plasmid SE (previously named HRSIN-CSEW 28 ) contains an SFFV LTR that drives an eGFP expression cassette that was used to construct WASpexpressing vectors.
Lentiviral vector constructs
The lentiviral vector backbone used for this study has been described previously. 28 To construct SW, the WPRE Lentiviral vectors transcriptionally targeted to hematopoietic cells F Martín et al sequence was eliminated from the SE vector and the WASP cDNA amplified by RT-PCR inserted into the SE vector in place of the eGFP. The SW vector drives the expression of the WASP gene by the strong promoter from SFFV LTR. The proximal WASP gene promoter (extending from bases À1 to À499 from the transcriptional start site) was derived by PCR from genomic DNA using the following primers: 5 0 CCGGAATTCGGGATT ACAGGTGTGAGC3 0 and 5 0 CGCGGATCCGGTGCTTTC TGCCCTTGTCTTC3 0 . The WW vector was constructed by EcoRI and BamHI restriction enzyme digestion and ligation of the SW vector and the PCR product. This excised the SFFV LTR promoter sequences and replaced them by the 500 bp fragment containing the 5 0 proximal WASP promoter. WE vector was constructed by replacing the WASP gene cDNA from the WW vector with the eGFP cDNA from the pHRSin18-SFFV LTR plasmid 28 by double restriction enzyme digestion and ligation with BamHI-XhoI.
Vector production
Lentiviral vectors were produced by cotransfection of 293T cells with three plasmids: (1) vector plasmid (SE, WE, SW or WW), (2) packaging plasmid pCMVDR8.91 and (3) envelope plasmid pMD.G, as described previously. 41 Briefly, 293T cells (6 Â 10 6 ) were plated on a 10-cm tissue culture-grade Petri dish (Sarstedt, Newton, NC, USA) the day before transfection to ensure exponential growth and 80% confluence. Vector plasmids, together with packaging and envelope plasmids (27 mg total DNA; plasmid proportions of 3:2:1, respectively), were resuspended in 1.5 ml of OPTI-MEM media (Gibco) and mixed at room temperature for 20 min with 60 ml of Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) and then diluted in 1.5 ml of OPTI-MEM. The plasmidlipofectamine mixture was added to prewashed cells and then incubated for 6-8 h. The producer cells were then washed and further cultured for 48 h in 10 ml of OPTI-MEM media. Viral supernatants were collected and filtered through a 0.45 mm filter (Nalgene, Rochester, NY, USA), aliquoted and immediately frozen at À801C.
Cell transduction and vector titration
Exponentially growing target cells were washed in PBS, and 2 Â 10 5 cells were seeded per well in 500 ml of their appropriate media in 24-well plates. Supernatants were added to the culture and incubated overnight. After 72-h incubation or when indicated, cells were collected, washed, fixed in 0.2% of paraformaldehyde and analyzed in a FACScan Flow Cytometer (Becton-Dickinson, San Jose, CA, USA). Viral titers (transduction units/ml) were calculated based on the initial amount of target cells and the percentage of GFP + or WASp + cells detected in the linear range of a serial dilution of the supernatant. The MOI is defined as the number of viral vectors per cell, and was estimated over the HVS-WAS/1 cell line. This was required since the WW vectors are not expressed in non-HCs such as 293T, and should therefore be assayed on a hematopoietic WASp-deficient cell line.
Mouse hematopoietic progenitors transduction and methylcellulose colony assay
Bone marrow cells pooled from four Balb/c mice were harvested and Sca1 + cells selected using MACS immunomagnetic columns (Miltenyi Biotec, Germany). Briefly, 4 Â 10 7 bone marrow cells were incubated with 50 ml of magnetic-labeled Sca-1 antibodies (Miltenyi) and passed through the columns. After two washes with PBS, Sca1 + cells were eluted with RPMI containing 30% of FCS and supplemented with a cytokine cocktail (murine Scf 100 ng/ml; IL-6 20 ng/ml; mFlt-3L 10 ng/ml) (StemCell Technologies, Vancouver, Canada). Cells were plated at a concentration of 10 6 cells/ml and incubated O/N with lentiviral vectors' supernatant (MOI ¼ 1 estimated over HVS-WAS/1 cells). Cells were then washed and incubated in Iscove's modified Dulbecco's medium (IMDM) media (Gibco) and 500 ml containing 10 4 cells were mixed with 2.5 ml of Metho Cult media (StemCell Technologies). Cells were cultured in 35 mm Petri dishes at 371C and 5% of CO 2 . Stem cell colonies were counted and analyzed after 20 days.
Human hematopoietic progenitors transduction and methylcellulose colony assay
Human cord blood was obtained from placental and umbilical tissues and diluted 1:3 in IMDM (Gibco). Mononuclear cells were collected by density centrifugation (Ficoll-Hypaque, Pharmacia Biotech, Uppsala, Sweden) and the CD34 + subset isolated using a-CD34 MACS immunomagnetic columns (Miltenyi) as described above. Cells were analyzed by flow cytometry immediately after purification for CD34 + expression using a PE-a-CD34 antibody (Miltenyi). The percentage of CD34 + cells was typically higher than 85%. 
Immunostaining and flow cytometry
After 72 h or other times if indicated, cells were collected, washed and permeabilized with Citofix/cytoperm (Pharmingen, San Diego, CA, USA) following the manufacturer's recommendations. Cells were subsequently washed and preincubated in a PBS-blocking solution containing 2% normal goat serum and 0.05% saponin for 20 min at 41C. After washes, intracellular staining of WASp was carried out by indirect immunofluorescence, using 2 mg of anti-WASp monoclonal antibody B9 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) diluted in 200 ml of blocking solution and incubated at 41C for 1 h with continuous agitation in an orbital shaker. Cells were washed in PBS-0.02% saponin and incubated again with 2 mg of an FITC-labeled goat anti-mouse IgG antisera (Caltag Laboratories, Burlingame, CA, USA) (diluted in PBS-0.05% saponin) for 45 min at 41C in continuous agitation. Cells were washed 2 Â in PBS-0.02% saponin followed by a final wash in PBS alone. Cells were analyzed in the FACScan Flow Cytometer.
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SDS-PAGE, semiquantitative and quantitative Western immunoblotting
Cells were lysed with 1% NP-40 lysis buffer containing protease inhibitor cocktail (Sigma, St Louis, MO, USA), resolved by SDS-PAGE (10% polyacrylamide gels, reducing conditions) and electrotransferred to Hybond-P PVDF membranes (Amersham, Buckinghamshire, UK). Membranes were blocked with 5% nonfat milk and probed for 1 h at room temperature with 1 mg/ml of the anti-WASp mAb D1 (Santa Cruz Biotechnology) followed by incubation with HRPO-labeled goat antimouse antibody (1:10 000 dilution) (Caltag). The blot was developed by chemiluminescence (ECL, Amersham) and exposed to autoradiographs (Amersham). Loading controls were carried out by rehybridization of stripped membranes with an a-Erk polyclonal antibody (anti-MAP kinase 1/2, Upstate Biotechnology, UK). Semiquantitative analysis was carried out by densitometric scanning of bands using the Quantity One version 4.5.0 software (Bio-Rad).
Quantitative Western blot analysis was performed using the ECL Advanced Western Blotting Detection Kit (Amersham Bioscience, UK). Membranes were blotted and probed as above, but were revealed by incubation for 1-5 min with a mixture of ECL Advanced reagents. Quantification of light emission was detected using a QuemiDoc XRS instrument (Bio-Rad Laboratories, Hercules, CA, USA) and analyzed at 440 nm with Quantity One version 4. 
